Galapagos NV (LON: 0JXZ)

London flag London · Delayed Price · Currency is GBP · Price in EUR
22.90
+0.23 (1.01%)
At close: Jan 22, 2025
-33.48%
Market Cap 1.28B
Revenue (ttm) 216.44M
Net Income (ttm) 171.70M
Shares Out n/a
EPS (ttm) 2.61
PE Ratio 7.45
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,105
Average Volume 9,601
Open 22.76
Previous Close 22.67
Day's Range 22.72 - 23.04
52-Week Range 18.07 - 32.29
Beta 0.06
RSI 30.92
Earnings Date Feb 12, 2025

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 1,123
Stock Exchange London Stock Exchange
Ticker Symbol 0JXZ
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.